Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma

#431

Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels

Aim(s): Considering persistent hypoglycemic syndrome, Everolimus was introduced.

Materials and methods: Everolimus 10 mg daily was administered in combination with radiometabolic treatment.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Ferrero A, Bellini E, Brizzi M, Pia A, Ottone A,

Keywords: malignant insulinoma, everolimus, resistant hypoglycemia,